Chutes & Ladders—Former Legend CEO lands at K2

Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed round from MPM BioImpact.